UPDATE: EMA tries 'new approach' to aid gene therapy development
This article was originally published in SRA
Developers of gene therapies tend not to be familiar with the regulatory environment and so the European Medicines Agency is trying a new approach aimed at addressing their needs in a new draft guideline aimed at supporting and facilitating the development of such products1,2.
You may also be interested in...
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.